Jooeun Bae

Directeur/Bestuurslid bij OncoPep, Inc.

Finance

Momenteel actieve connecties

Naam	Geslacht	Leeftijd	Verwante bedrijven	Samenwerking
Doris Peterkin	F	-	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	14 jaar
Joslyn Dobson	F	-	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	14 jaar
Bruce Downey	M	76	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	13 jaar
Elena Prokupets	M	69	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	-
Jay L. Eastman	M	-	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	-
Kenneth Anderson	M	72	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	14 jaar
Nikhil C. Munshi	M	-	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	-
Victor Moyo	M	-	OncoPep, Inc. OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.	2 jaar